Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion
about
Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysisAbatacept for rheumatoid arthritisDifferentiation of naive CD4+ T cells towards T helper 2 cells is not impaired in rheumatoid arthritis patientsBiologic interventions for fatigue in rheumatoid arthritisTowards prevention of autoantibody-positive rheumatoid arthritis: from lifestyle modification to preventive treatmentCellular targeting in autoimmunityBiologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritisCo-stimulatory pathways in lymphocyte regulation: the immunoglobulin superfamilyBiologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials.CTLA4Ig prevents initiation but not evolution of anti-phospholipid syndrome in NZW/BXSB mice.The evolving clinical profile of abatacept (CTLA4-Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritis.The role of the T cell in autoimmune inflammation.Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted BiologicsInfections requiring hospitalization in the abatacept clinical development program: an epidemiological assessment.Phase III, multicenter, open-label, long-term study of the safety of abatacept in Japanese patients with rheumatoid arthritis and an inadequate response to conventional or biologic disease-modifying antirheumatic drugs.Immune suppression in cynomolgus monkeys by XPro9523: an improved CTLA4-Ig fusion with enhanced binding to CD80, CD86 and neonatal Fc receptor FcRnImmunotherapeutic strategies in autoimmune uveitisCTLA4Ig: a novel inhibitor of costimulation.CTLA4-Ig interacts with cultured synovial macrophages from rheumatoid arthritis patients and downregulates cytokine production.Abatacept: the evidence for its place in the treatment of rheumatoid arthritis.Abatacept.Abatacept: a costimulatory inhibitor for treatment of rheumatoid arthritis.Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period.Signal one and two blockade are both critical for non-myeloablative murine HSCT across a major histocompatibility complex barrier.T cell costimulatory pathways: blockade for autoimmunity.The therapeutic potential of costimulatory blockade with CTLA4Ig in rheumatoid arthritis.Immunotherapy for autoimmune and inflammatory renal diseases.Clinical trials of transplant tolerance: slow but steady progress.T-cell involvement in osteoclast biology: implications for rheumatoid bone erosion.Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan.T cells, fibroblast-like synoviocytes, and granzyme B+ cytotoxic cells are associated with joint damage in patients with recent onset rheumatoid arthritisImmunosuppressants in advanced clinical development for organ transplantation and selected autoimmune diseases.Clinical islet transplant: current and future directions towards tolerance.Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial.Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatmentSystemic arthritis in children: a review of clinical presentation and treatmentCD40 blockade combines with CTLA4Ig and sirolimus to produce mixed chimerism in an MHC-defined rhesus macaque transplant model.
P2860
Q24185797-3DA015EB-36A9-46F5-81E0-B84ADD346699Q24240131-006B5BE0-EF17-4C83-BA1D-948C249A515BQ24797604-D9C5D9A7-9F7D-42C6-A2AA-ACCD0FE02D4BQ26471538-45A4B1B5-258F-47D2-8655-19D60A30B563Q26786705-6344204A-7400-4C32-897D-F06700961882Q26824580-43C47960-28A3-4D2F-943C-008D8604C2F7Q26852235-58A07D67-96E7-4C76-83B7-BED8210BA690Q28271806-E3298DB3-DC79-4C6C-92DE-260585D428DAQ30234528-37CA22F2-D0CB-48D7-8C17-75280D14BD92Q30235341-09412398-97DD-447C-AD38-71A65719593DQ33315300-DA9C4D87-D6B6-456E-9845-5B8547F759CDQ33364310-70EF1832-0B4F-4EC9-8B43-A2AB093F8614Q33709339-B190A5A1-D600-4930-9598-08E3D77EC5CBQ33709343-ED035588-5A73-4701-9314-DEB718AEAE71Q33809045-56090B35-E5D0-4FB9-A33D-D246DCC42C0CQ33923452-5242C4F2-36C7-405D-A291-4C06EC5AD4D7Q34172853-18B2737C-015E-4E5D-8536-76FB701D91D3Q34212755-EAEE281E-5450-415B-9FA1-C8E979E09BC2Q34274950-A7C8169E-6F13-4E5E-9468-9A5F923E32EFQ34330606-23AC5703-DA78-4E44-BCD9-608E34ADD04BQ34413292-3CD69A54-332F-4B3D-AFFB-F073711774A7Q34449851-70280227-A364-43CD-8504-C9A474E4F499Q34504843-E89C5F56-2040-41AA-B029-EDF12354AD69Q34560362-4235DF4D-984D-417D-A6F0-387E9B8D142EQ34818608-B37A6643-A1C5-40BD-B42F-088339E00C32Q35023283-0D04A83A-3C5A-4540-B087-53C6D6219888Q35093604-1BCDDB1E-6212-420F-8B09-27900D620CEFQ35094697-D9CCFFE9-AA8C-4B85-9EA0-B9A1D240A54EQ35144046-B697CF82-D0B1-4264-B27E-0C8F63F6A894Q35157558-59784BAB-F205-4128-8104-CE6E7C558921Q35179608-A70E169F-C9F3-4243-AC3A-7907A86C122BQ35214632-BA53E526-4411-4CCD-92DF-6BE17B80F97CQ35554105-AB5F1233-6C49-4EAC-96D9-5B274E5BB999Q35581131-ACBDF960-61A3-49CB-9B60-64CD5894085AQ35583539-7631DF64-99C3-44F4-A1CC-EDC551B0559FQ35638252-D13FAA04-411A-459B-9725-1AF661F33BDEQ35638718-DDB8D169-8DFD-43C2-B3AF-4DE77723C904Q35638735-B56B5E47-C5E3-4E98-AD68-9D3523F41777Q35659928-FE69C923-13A1-4346-A0DF-624AAB6FB01EQ35675258-553B3F67-A32B-4A27-845E-6883182384B6
P2860
Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion
description
article
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в червні 2002
@uk
name
Costimulatory blockade in pati ...... days after the first infusion
@en
Costimulatory blockade in pati ...... days after the first infusion
@nl
type
label
Costimulatory blockade in pati ...... days after the first infusion
@en
Costimulatory blockade in pati ...... days after the first infusion
@nl
prefLabel
Costimulatory blockade in pati ...... days after the first infusion
@en
Costimulatory blockade in pati ...... days after the first infusion
@nl
P2093
P2860
P356
P1476
Costimulatory blockade in pati ...... days after the first infusion
@en
P2093
Filip Van den Bosch
Isaac Nuamah
Jean-Claude Becker
Larry W Moreland
Michael Luggen
Rieke Alten
Stanley Cohen
Thierry Appelboom
William Shergy
P2860
P304
P356
10.1002/ART.10294
P407
P50
P577
2002-06-01T00:00:00Z
P6179
1053388835